Clinical Trial Update: A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic study of CNTO 136 in patients with cutaneous lupus erythematosus and systemic lupus erythematosus; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• CNTO 136

Snippet

Sponsor: Centocor Research & Development, Inc. | Conditions: Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic | Phase 1 | Status: COMPLETED